English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Systematic evaluation of fluorination as modification for peptide-based fusion inhibitors against HIV-1 infection

MPS-Authors
/persons/resource/persons213998

Roth,  Christian
Christian Roth, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Article.pdf
(Publisher version), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Huhmann, S., Nyakatura, E., Rohrhofer, A., Moschner, J., Schmidt, B., Eichler, J., et al. (2021). Systematic evaluation of fluorination as modification for peptide-based fusion inhibitors against HIV-1 infection. Chembiochem, 22(24), 3443-3451. doi:10.1002/cbic.202100417.


Cite as: https://hdl.handle.net/21.11116/0000-0009-623E-4
Abstract
With the emergence of novel viruses, the development of new antivirals is more urgent than ever. A key step in human immunodeficiency virus type 1 (HIV-1) infection is six-helix bundle formation within the envelope protein subunit gp41. Selective disruption of bundle formation by peptides has been shown to be effective; however, these drugs, exemplified by T20, are prone to rapid clearance from the patient. The incorporation of non-natural amino acids is known to improve these pharmacokinetic properties. Here, we evaluate a peptide inhibitor in which a critical Ile residue is replaced by fluorinated analogues. We characterized the influence of the fluorinated analogues on the biophysical properties of the peptide. Furthermore, we show that the fluorinated peptides can block HIV-1 infection of target cells at nanomolar levels. These findings demonstrate that fluorinated amino acids are appropriate tools for the development of novel peptide therapeutics.